INVESTOR ALERT: LEVI & KORSINSKY, LLP Announces Investigation of CADENCE PHARMACEUTICALS INC. & Its Board of Directors in Con...
February 13 2014 - 5:33PM
Business Wire
Levi & Korsinsky is investigating the Board of Directors of
Cadence Pharmaceuticals Inc. (“Cadence” or “the Company”)
(NasdaqGS:CADX) for possible breaches of fiduciary duty and other
violations of state law in connection with the sale of the Company
to Mallinckrodt plc.
Click here to learn more about the action
http://zlk.9nl.com/cadence-pharmaceuticals-cadx, or call:
877-363-5972. There is no cost or obligation to you.
Under the terms of the transaction, Cadence shareholders will
receive $14.00 for each share of Cadence common stock they own. The
investigation concerns whether the Cadence Board breached their
fiduciary duties to stockholders by failing to adequately shop the
Company before agreeing to enter into this transaction, and whether
Mallinckrodt plc is underpaying for Cadence shares. In particular,
at least one analyst set a price target for Cadence stock at $15.00
per share.
If you own Cadence common stock and wish to obtain additional
information, please contact Joseph E. Levi, Esq. either via email
at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free:
(877) 363-5972, or visit
http://zlk.9nl.com/cadence-pharmaceuticals-cadx.
Levi & Korsinsky is a national firm with offices in New
York, New Jersey, Connecticut and Washington D.C. The firm’s 26
attorneys have extensive expertise in prosecuting securities
litigation involving financial fraud, representing investors
throughout the nation in securities and shareholder lawsuits. For
more information, please feel free to contact any of the attorneys
listed below. Attorney advertising. Prior results do not guarantee
similar outcomes.
Levi & Korsinsky, LLPJoseph Levi, Esq.Eduard Korsinsky,
Esq.Tel: 212-363-7500Toll Free: 877-363-5972Fax:
866-367-6510www.zlk.com
(MM) (NASDAQ:CADX)
Historical Stock Chart
From Oct 2024 to Nov 2024
(MM) (NASDAQ:CADX)
Historical Stock Chart
From Nov 2023 to Nov 2024